Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Eur Spine J ; 32(12): 4335-4354, 2023 12.
Artículo en Inglés | MEDLINE | ID: mdl-37707603

RESUMEN

BACKGROUND CONTEXT: Patients with multiple myeloma (MM) are at increased risk of infections and suffer from poor bone quality due to their disseminated malignant bone disease. Therefore, postoperative complications may occur following surgical treatment of MM lesions. PURPOSE: In this study, we aimed to determine the incidence of postoperative complications and retreatments after spinal surgery in MM patients. Additionally, we sought to identify risk factors associated with complications and retreatments. STUDY DESIGN: Retrospective cohort study. PATIENT SAMPLE: In total, 270 patients with MM who received surgical treatment for spinal involvement between 2008 and 2021 were included. OUTCOME MEASURES: The incidence of perioperative complications within 6 weeks and reoperations within 2.5 years and individual odds ratios for factors associated with these complications and reoperations. METHODS: Data were collected through manual chart review. Hosmer and Lemeshow's purposeful regression method was used to identify risk factors for complications and reoperations. RESULTS: The median age of our cohort was 65 years (SD = 10.8), and 58% were male (n = 57). Intraoperative complications were present in 24 patients (8.9%). The overall 6-week complication rate after surgery was 35% (n = 95). The following variables were independently associated with 6-week complications: higher Genant grading of a present vertebral fracture (OR 1.41; 95% CI 1.04-1.95; p = .031), receiving intramuscular or intravenous steroids within a week prior to surgery (OR 3.97; 95% CI 1.79-9.06; p = .001), decompression surgery without fusion (OR 6.53; 95% CI 1.30-36.86; p = .026), higher creatinine levels (OR 2.18; 95% CI 1.19-5.60; p = .014), and lower calcium levels (OR 0.58; 95% CI 0.37-0.88; p = .013). A secondary surgery was indicated for 53 patients (20%), of which 13 (4.8%) took place within two weeks after the initial surgery. We additionally discovered factors associated with retreatments, which are elucidated within the manuscript. CONCLUSION: The goal of surgical treatment for MM bone disease is to enhance patient quality of life and reduce symptom burden. However, postoperative complication rates remain relatively high after spine surgery in patients with MM, likely attributable to both inherent characteristics of the disease and patient comorbidities. The risk for complications and secondary surgeries should be explored and a multidisciplinary approach is crucial.


Asunto(s)
Enfermedades Óseas , Mieloma Múltiple , Fusión Vertebral , Humanos , Masculino , Anciano , Femenino , Estudios Retrospectivos , Mieloma Múltiple/epidemiología , Mieloma Múltiple/cirugía , Calidad de Vida , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Enfermedades Óseas/complicaciones , Fusión Vertebral/métodos
2.
Int J Clin Pharm ; 40(5): 1402-1408, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29948741

RESUMEN

Background The combination of combined active antiretroviral therapy (cART) with chemotherapy in the treatment of lymphoma in human immunodeficiency virus (HIV)-positive patients has improved the overall survival of these patients. However, drug-drug interactions between antineoplastic agents and the antiretroviral agents non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) can occur by influencing the activity of the CYP3A4 enzyme. So far, little is known about the clinical relevance of this interaction: the effect on the efficacy and toxicity of the chemotherapy. Also, there is no general consensus which cART is preferable in combination with antineoplastic drugs. Objective To compare PI-based with NNRTI-based cART on the efficacy and toxicity of chemotherapy in lymphoma patients. Setting The Onze Lieve Vrouwe Gasthuis, located in Amsterdam, The Netherlands. Method A retrospective observational cohort study including all patients with HIV and lymphoma over a 10-year period. Clinical outcome (response to chemotherapy and survival) and toxicity of chemotherapy (renal, hepatic and bone marrow toxicity as well as dose reduction, treatment delay and discontinuation) was compared in patients with PI based and NNRTI-based cART. Main outcome measure: Response to chemotherapy and survival. Results Patients using PI-based cART (n = 22) had a significantly lower 1 year survival compared to NNRTI-based cART (n = 21). No significant differences were observed in reaching complete remission after chemotherapy. No overall significant differences in toxicity and discontinuation of the chemotherapy were observed. However, there was a trend towards more severe bone-marrow toxicity in patients with PI-based cART. In addition, patients with PI-based cART received earlier dose-reduction and treatment delay, indicating increased toxicity in PI-treated patients. Conclusion This retrospective study shows that PI-based cART is inferior in combination with chemotherapy to NNRTI-based cART: a lower 1 year survival is observed and dose-reduction and treatment delay occur earlier, possibly based on an earlier onset of toxicity.


Asunto(s)
Fármacos Anti-VIH/administración & dosificación , Antineoplásicos/administración & dosificación , Infecciones por VIH/tratamiento farmacológico , Linfoma/tratamiento farmacológico , Adulto , Anciano , Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/farmacología , Estudios de Cohortes , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Femenino , Inhibidores de la Proteasa del VIH/administración & dosificación , Inhibidores de la Proteasa del VIH/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Países Bajos , Estudios Retrospectivos , Inhibidores de la Transcriptasa Inversa/administración & dosificación , Inhibidores de la Transcriptasa Inversa/efectos adversos , Tasa de Supervivencia , Resultado del Tratamiento
4.
Neth J Med ; 68(2): 87-90, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20167961

RESUMEN

An HIV-positive man from Somalia presented with severe malaise, weight loss, relapsing fever, lymphadenopathy and splenomegaly. An FDG-PET-scan-guided lymph node biopsy revealed the characteristic histological features of the plasma cell variant of Castleman's disease. A high HHV-8 viral load was detected in the serum (7980 copies/ml). Treatment with HAART, rituximab and vinblastine resulted in a full and rapid recovery and lowered HHV-8 viral load to undetectable levels.


Asunto(s)
Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Antineoplásicos Fitogénicos/uso terapéutico , Terapia Antirretroviral Altamente Activa , Enfermedad de Castleman/tratamiento farmacológico , Infecciones por VIH/tratamiento farmacológico , Vinblastina/uso terapéutico , Enfermedad de Castleman/sangre , Enfermedad de Castleman/virología , Infecciones por VIH/virología , Herpesvirus Humano 8/fisiología , Humanos , Factores Inmunológicos/uso terapéutico , Masculino , Persona de Mediana Edad , Pronóstico , Rituximab
5.
Ned Tijdschr Geneeskd ; 150(35): 1936-43, 2006 Sep 02.
Artículo en Holandés | MEDLINE | ID: mdl-16999279

RESUMEN

A 39-year-old man was referred from Surinam to the Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands, for a right ventricular tumour, hypereosinophilia and mild thrombocytopenia. He appeared to have chronic eosinophilic leukaemia that was positive for the 'FIP1-like-1-platelet-derived growth factor receptor alpha' (FIP1L1-PDGFRA) gene. In addition, he had signs of a right ventricular thrombus that had existed for at least 6 months. The patient was treated with oral anticoagulants and the tyrosine kinase inhibitor imatinib. The latter therapy resulted in normalisation of leukocyte count and differential values. After 3 months of therapy, the FIP1L1-PDGFRA fusion transcript was no longer detectable in peripheral blood. After 1 year of follow up, the patient was in complete haematological and molecular remission for chronic eosinophilic leukaemia. The cardiac mass remained unchanged, but caused no haemodynamic problems.


Asunto(s)
Antineoplásicos/uso terapéutico , Síndrome Hipereosinofílico/tratamiento farmacológico , Síndrome Hipereosinofílico/genética , Piperazinas/uso terapéutico , Pirimidinas/uso terapéutico , Receptor alfa de Factor de Crecimiento Derivado de Plaquetas/genética , Adulto , Anticoagulantes/uso terapéutico , Benzamidas , Regulación Neoplásica de la Expresión Génica , Humanos , Mesilato de Imatinib , Masculino , Inhibidores de Proteínas Quinasas/uso terapéutico , Inducción de Remisión , Resultado del Tratamiento
6.
Transplantation ; 71(1): 47-52, 2001 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-11211194

RESUMEN

BACKGROUND: The treatment of posttransplant lymphoproliferative disorder (PTLD) remains empirical. We review our treatment of seven cases of PTLD consisting of five interventions: 1) reduction of immunosuppression; 2) antiviral drugs; 3) interferon-alpha; 4) gamma-globulins; and 5) anti-CD19 monoclonal antibodies. METHODS AND RESULTS; Seven consecutive patients who had undergone a simultaneous pancreas-kidney, liver, heart, or kidney transplantation were treated. One patient acquired a primary EBV infection with an oligoclonal immunoblastic lymphoma early after pancreas-kidney transplantation; all others developed a monoclonal polymorphic or immunoblastic lymphoma 2 to 123 months after transplantation. In all patients extranodal sites were involved, in three the graft was also involved. Five patients received the full quintuple approach and all rapidly obtained a complete remission (CR) with a median follow-up of 31 months (7-74 months). Of the two patients who did not receive interferon-alpha for fear of graft rejection one responded slowly with a CR after 7 months, and the other obtained a rapid CR followed by a relapse at 4 months. All three patients with a liver or heart transplant could keep their graft. All patients are still alive with a median follow-up of 31 months (7-74 months). CONCLUSION: This combined approach resulted in a favorable outcome in patients with high risk monoclonal PTLD after solid organ transplantation.


Asunto(s)
Trastornos Linfoproliferativos/etiología , Trastornos Linfoproliferativos/cirugía , Trasplante de Órganos/efectos adversos , Aciclovir/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Antivirales/uso terapéutico , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Interferón-alfa/uso terapéutico , Trastornos Linfoproliferativos/tratamiento farmacológico , Pronóstico , Inducción de Remisión , Resultado del Tratamiento
7.
Br J Haematol ; 82(1): 46-9, 1992 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-1419801

RESUMEN

In 54 patients with multiple myeloma plasma cell infiltration was compared in bone marrow biopsies and aspirates. In 48% of cases plasma cell infiltration was comparable, in 48% infiltration in the aspirate was lower than in the biopsy. In only two cases more plasma cells were found in the aspirate. Eleven patients (20%) had less than 20% plasma cells in the aspirate and more than 50% in the biopsy. Underestimation of plasma cell load especially seems to occur in patients with a focal growth pattern of multiple myeloma or when strong fibrosis is present. 69% of patients with stage III, according to Durie & Salmon (1975), and 76% of patients with a high beta 2-microglobulin had more than 50% plasma cells in the biopsy, indicating that these parameters, which are based on tumour load, are influenced by other factors as well. The bone marrow biopsy is of superior value for direct estimation of the tumour load in multiple myeloma compared to bone marrow aspirates. A prospective study is needed to determine its prognostic significance.


Asunto(s)
Médula Ósea/patología , Mieloma Múltiple/patología , Células Plasmáticas/patología , Anciano , Anciano de 80 o más Años , Biopsia , Biopsia con Aguja , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/sangre , Proteínas de Neoplasias/sangre , Estadificación de Neoplasias , Microglobulina beta-2/análisis
8.
Neth J Med ; 38(5-6): 254-6, 1991 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-1922598

RESUMEN

A 79-yr-old man was known for a year with a deteriorating clinical condition, vague abdominal complaints and an elevated erythrocyte sedimentation rate; he was afebrile. Extensive evaluation revealed no cause for his progressive disease. Eventually an infected aneurysm of the abdominal aorta was diagnosed, from which Listeria monocytogenes was cultured. After resection of the aneurysm the patient recovered initially very well. Regrettably, therapy-resistant chylous ascites developed, and the patient died due to surgical complications following a second laparotomy. Infected aortic aneurysms can present as an insidious disease, which may have catastrophic consequences if undiagnosed. A high index of suspicion is required to make a correct diagnosis. L. monocytogenes is an emerging, food-borne pathogen that can cause a wide spectrum of human diseases.


Asunto(s)
Aneurisma Infectado , Aneurisma de la Aorta/microbiología , Listeriosis , Anciano , Aorta Abdominal , Humanos , Masculino
9.
Am J Clin Pathol ; 94(6): 786-90, 1990 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-2244596

RESUMEN

The spontaneous and simultaneous occurrence of multiple myeloma and megakaryoblast leukemia with myelodysplastic features in a case of spent phase polycythemia vera is well documented. In support of the morphologic characteristics of the bone marrow, immunocytologic studies show proliferation of monoclonal plasma cells and megakaryoblasts. The cytogenetic findings of 20q- and unbalanced t(1;7) are consistent with myelodysplastic and leukemic transformation of the bone marrow. These transformations expand observations on variable and spontaneous lineage commitments as the consequence of alterations of the hematopoietic stem cell clone. These data are in support of the changing insights in hematopoiesis as a process of ordered commitment of the stem cell with sequential lineage potentials.


Asunto(s)
Leucemia Megacarioblástica Aguda/complicaciones , Mieloma Múltiple/complicaciones , Policitemia Vera/complicaciones , Médula Ósea/patología , Transformación Celular Neoplásica/patología , ADN de Neoplasias/genética , Hematopoyesis , Células Madre Hematopoyéticas/patología , Humanos , Cariotipificación , Leucemia Megacarioblástica Aguda/patología , Masculino , Megacariocitos/patología , Persona de Mediana Edad , Mieloma Múltiple/patología , Células Plasmáticas/patología , Policitemia Vera/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA